Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 28, 2025 06:24 ET | Source: Freya Pharma Solutions

Freya Pharma Solutions Strengthens Leadership with Appointment of Distinguished Supervisory Board

www.freyapharmasolutions.com Manuel Voll - James E. Hattersley - Dr. Inez de Greef Amsterdam, the Netherlands, 28 January 2025 - Freya Pharma Solutions, [Freya Pharma, or the Company], a...
November 21, 2022 09:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results

R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint ventureG&A cost reduced by approximately 50%Net loss reduced by approximately...
September 14, 2022 08:15 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
August 17, 2022 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Participating at Biotechgate Digital Partnering

AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
September 01, 2021 12:00 ET | Source: Oncotelic Therapeutics, Inc.

ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.

AGOURA HILLS, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), executed a binding term sheet with Autotelic Inc. to license AL-101...